Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selexys Pharmaceuticals Corp.

www.selexys.com

Latest From Selexys Pharmaceuticals Corp.

Keeping Track: A Week Of Calm As Shutdown Drags On

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

Venture Funding Deals: Four $100m-Plus Rounds, Including Allogene's $300m

April had four VC rounds of $100m or more, including Allogene's $300m to develop CAR-T therapies licensed from Pfizer. Innovent Biologics raised $150m, BenevolentAI brought in $115m and Constellation garnered $100m last month.

Financing StartUps and SMEs

Finance Watch: Former Alexion Execs Raise $37m To Launch Rare-Disease Focused RallyBio

Private Company Edition: Martin Mackay and two other former Alexion executives co-founded the rare disease start-up in January with a $37m Series A to kick things off. Also, Innovent raises $150m in venture cash, Tmunity adds $35m and Third Rock launches Cedilla.

Financing StartUps and SMEs

Emmaus Plans Modest Pricing In 4Q Rollout Of Sickle Cell Drug Endari

With an eye on a patient population mainly covered by Medicare and Medicaid, Emmaus Life Sciences CEO Yutaka Niihara says the company wants to ensure its pharmaceutical grade L-glutamine product is accessible in the US.

Approvals Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Gastrointestinal
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Selexys Pharmaceuticals Corp.
  • Senior Management
  • Scott Rollins, PhD, Pres. & CEO
    David Falconer, VP, Bus. & Drug Dev.
    Richard D Cummings, PhD, CSO
  • Contact Info
  • Selexys Pharmaceuticals Corp.
    Phone: (405) 319-8195
    840 Research Pkwy.
    Ste. 510
    Oklahoma City, OK 73104
    USA
UsernamePublicRestriction

Register